In a retrospective study on 200 general COVID-19 patients who were treated with arbidol hydrochloride or in combination with Shufengjiedu capsules, it was found that patients treated with arbidol hydrochloride and Shufengjiedu capsules had a shorter time in defervescence, larger white blood cell counts, higher percentages of lymphocytes and lower serum C-reactive protein (CRP) as well as IL-6 than those treated with arbidol hydrochloride alone, respectively. This evidence concerns the gene CRP and COVID-19.